Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDNF | P23560 | 3/20 | 0.49 |
| ▸ | MDK | P21741 | 3/20 | 0.49 |
| ▸ | PTN | P21246 | 2/20 | 0.49 |
| ▸ | F10 | P00742 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 7/20 | 0.44 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS9 | O00182 | 2/20 | 0.42 |
| ▸ | SERPINC1 | P01008 | 1/20 | 0.40 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.40 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.40 |
| ▸ | F9 | P00740 | 2/20 | 0.38 |
| ▸ | CD69 | Q07108 | 1/20 | 0.38 |
| ▸ | F8 | P00451 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dermatan Sulfate SCHEMBL10157447 | 0.93 | MDK (0.54) | BDNFMDKPTNF10LGALS3 | |
| Dermatan Sulfate SCHEMBL25645152 | 0.93 | MDK (0.54) | BDNFMDKPTNF10LGALS3 | |
| Dermatan Sulfate SCHEMBL15144387 | 0.93 | MDK (0.54) | BDNFMDKPTNF10LGALS3 | |
| SCHEMBL13321922 | 0.88 | LGALS3 (0.49) | BDNFMDKPTNLGALS3LGALS7; LGALS7B | |
| SCHEMBL27097996 | 0.87 | MDK (0.47) | BDNFMDKPTNF10LGALS3 | |
| SCHEMBL27097975 | 0.85 | MDK (0.46) | BDNFMDKPTNF10LGALS3 | |
| SCHEMBL27097981 | 0.85 | MDK (0.45) | BDNFMDKPTNF10LGALS3 | |
| SCHEMBL27097990 | 0.85 | BDNF (0.57) | BDNFMDKPTNF10LGALS3 | |
| SCHEMBL23336378 | 0.85 | MDK (0.53) | BDNFMDKPTNF10LGALS3 | |
| SCHEMBL27097986 | 0.84 | MDK (0.48) | BDNFMDKPTNF10LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | GLYCOLOGIX INC (US) | 2024-07-18 | — | — | US | disclosed |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | GLYCOLOGIX, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238328-A1 | Sulfated Glycosaminoglycan Biomaterials as Proteoglycan Mimics | MATR3, CSGALNACT1, CD44 | BDNF 1027/4885MDK 801/4885PTN 44/4885 |
| US-11911411-B2 | Sulfated glycosaminoglycan biomaterials as proteoglycan mimics | MATR3, CSGALNACT1, CD44 | BDNF 1027/4885MDK 801/4885PTN 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.